PMID- 29174221
OWN - NLM
STAT- MEDLINE
DCOM- 20190408
LR  - 20191210
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 19
IP  - 2
DP  - 2018 Mar
TI  - Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: 
      Report of a Peculiar Case and Systematic Review of the Literature.
PG  - e151-e161
LID - S1525-7304(17)30302-9 [pii]
LID - 10.1016/j.cllc.2017.10.008 [doi]
AB  - Lung toxicity is a potential fatal effect involving non-small-cell lung cancer 
      (NSCLC) patients exposed to tyrosine kinase inhibitors (TKIs). Moving from our 
      experience regarding a patient who developed lung toxicity while receiving 2 
      different anaplastic lymphoma kinase (ALK)-TKIs, we performed a systematic review 
      to assess the epidemiologic magnitude and the clinical significance of such 
      toxicity in NSCLC patients treated with ALK-TKIs. Studies were identified using 
      MEDLINE and additional sources (European Society for Medical Oncology, American 
      Society of Clinical Oncology, and World Conference on Lung Cancer abstracts) in 
      agreement with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      and Cochrane guidelines. Lung toxicity was reported in 105 of 4943 NSCLC patients 
      (2.1%). Crizotinib was responsible for pulmonary adverse events (AEs) in 1.8% of 
      exposed patients (49 of 2706). With the limit of a lower number of treated 
      patients (n = 359), brigatinib resulted as the most frequently involved in lung 
      toxicity (7%; n = 25). Pulmonary AEs during therapy with ceritinib, alectinib, 
      and lorlatinib occurred in 1.1%, 2.6%, and 1.8% of the patients, respectively. 
      Sixty-five percent of cases accounted for Grade 3 or 4 events, with a mortality 
      rate of 9%. Radiological patterns of pneumonia were reported in 25 patients, 
      whereas imaging evocative of interstitial lung disease in 37. Overall, 26 of 105 
      patients (25%) permanently discontinued treatment because of lung toxicity. Lung 
      toxicity is a rare albeit potentially severe side effect in NSCLC patients 
      receiving ALK-TKIs, apparently more frequent with brigatinib. Its early 
      recognition and treatment are crucial for the best outcome of this subgroup of 
      patients, whose overall prognosis is being improved by the availability of 
      several targeted agents.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pellegrino, Benedetta
AU  - Pellegrino B
AD  - Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
FAU - Facchinetti, Francesco
AU  - Facchinetti F
AD  - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Electronic 
      address: francescofacchinetti2@gmail.com.
FAU - Bordi, Paola
AU  - Bordi P
AD  - Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
FAU - Silva, Mario
AU  - Silva M
AD  - Radiology Unit, University Hospital of Parma, Parma, Italy.
FAU - Gnetti, Letizia
AU  - Gnetti L
AD  - Pathology Section, University Hospital of Parma, Parma, Italy.
FAU - Tiseo, Marcello
AU  - Tiseo M
AD  - Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Systematic Review
DEP - 20171028
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 53AH36668S (Crizotinib)
RN  - 9842X06Q6M (Betamethasone)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - HYW8DB273J (brigatinib)
SB  - IM
MH  - Adult
MH  - Anaplastic Lymphoma Kinase/antagonists & inhibitors
MH  - Betamethasone/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/epidemiology/mortality
MH  - Crizotinib/adverse effects/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/mortality
MH  - Female
MH  - Humans
MH  - Italy/epidemiology
MH  - Lung Diseases, Interstitial/*epidemiology/etiology/mortality
MH  - Lung Neoplasms/*drug therapy/epidemiology/etiology/mortality
MH  - Organophosphorus Compounds/adverse effects/therapeutic use
MH  - Pneumonia/*epidemiology/etiology/mortality
MH  - Protein Kinase Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Pyrimidines/adverse effects/therapeutic use
MH  - Survival Analysis
MH  - Withholding Treatment/statistics & numerical data
OTO - NOTNLM
OT  - ALK inhibitors
OT  - Interstitial lung disease
OT  - NSCLC
OT  - Pneumonia
OT  - Toxicity
EDAT- 2017/11/28 06:00
MHDA- 2019/04/09 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/07/02 00:00 [received]
PHST- 2017/10/10 00:00 [revised]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2019/04/09 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - S1525-7304(17)30302-9 [pii]
AID - 10.1016/j.cllc.2017.10.008 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2018 Mar;19(2):e151-e161. doi: 10.1016/j.cllc.2017.10.008. Epub 
      2017 Oct 28.